GlassScriptPhysician profile
Mona Avanaki
NPI 1811646631
$1,911.18
in general payments reported to CMS, 2019-2025
18 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.50 · 2024: $567 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $400.25 | 2024-2025 | Rystiggo, Fintepla, Nayzilam |
| Abbvie INC. | $370.36 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $273.04 | 2024-2025 | Ultomiris |
| Argenx US, INC. | $119.53 | 2025 | Vyvgart |
| Acadia Pharmaceuticals INC | $117.97 | 2024-2025 | Nuplazid, Daybue |
| Neurelis, INC. | $108.36 | 2025 | Valtoco |
| Emd Serono, INC. | $96.43 | 2024-2025 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $79.36 | 2024-2025 | Hyqvia |
| Tg Therapeutics, INC. | $53.68 | 2025 | |
| Medtronic, INC. | $40.10 | 2024 | Linq II |
| Merz Pharmaceuticals, LLC | $38.37 | 2025 | Xeomin, Inbrija, Ampyra |
| Novartis Pharmaceuticals Corporation | $32.06 | 2025 | |
| Livanova USA, INC. | $31.77 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Astrazeneca Pharmaceuticals LP | $27.08 | 2025 | Wainua |
| Lundbeck LLC | $24.75 | 2024 | Vyepti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.58 | 2025 | |
| Acorda Therapeutics, INC | $19.19 | 2024 | Inbrija |
| Biogen, INC. | $18.80 | 2025 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Avanaki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.